DNABW — Ginkgo Bioworks Holdings, Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 1830214 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 20,156,000 | 18,437,000 | -58,548,000 | -46,710,000 | 990,046,000 | 84,535,000 | 569,762,000 |
| Mar 2026 | 19,474,000 | 16,376,000 | -71,374,000 | -82,587,000 | 1,033,075,000 | 143,864,000 | 589,922,000 |
| Dec 2025 | 33,396,000 | 26,095,000 | -70,046,000 | -80,751,000 | 1,119,696,000 | 167,202,000 | 611,106,000 |
| Sep 2025 | 38,837,000 | 26,035,000 | -88,272,000 | -80,755,000 | 1,189,165,000 | 111,065,000 | 629,382,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-178,360,000
Investing CF
$56,502,000
Financing CF
$34,550,000
CapEx
$-4,595,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-6,279,617,000
Inventory
—
Receivables
$13,013,000
ST Investments
$217,628,000
EBIT TTM
$-297,960,000
Pretax Income TTM
$-295,480,000
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$132,421,000
EBITDA
$-261,624,992
Free Cash Flow
$-72,398,248
Enterprise Value
—
Total Cash
$302,163,008
Total Debt
$404,112,992
Shares Out
—
Trailing EPS
—
Book Value
$6.60
ROE
-59.9%
ROA
-16.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 170,155,000 | -303,880,000 | -312,763,000 | 1,119,696,000 | 611,106,000 | — | -171,059,000 |
| Dec 2024 | 227,043,000 | -487,727,000 | -547,029,000 | 1,377,449,000 | 661,391,000 | — | -319,585,000 |
| Dec 2023 | 251,455,000 | -768,196,000 | -892,869,000 | 1,665,342,000 | 568,190,000 | — | -295,500,000 |
| Dec 2022 | 477,706,000 | -2,208,952,000 | -2,104,929,000 | 2,539,321,000 | 803,044,000 | — | -252,198,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $239.95B | $443.84 | — |
| GILD | GILEAD SCIENCES, INC. | $181.95B | $146.74 | — |
| ARGX | ARGENX SE | $63.26B | $1011.11 | — |
| MRNA | Moderna, Inc. | $55.45B | $138.89 | — |
| RVMD | Revolution Medicines, Inc. | $45.35B | $211.58 | — |
News headlines (Yahoo Finance, 1h cache)
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
2026-08-11 18:00 · Yahoo
Ginkgo Bioworks Q2 Earnings Call Highlights
2026-08-08 04:03 · Yahoo
Ginkgo Bioworks Holdings, Inc. Q2 2026 Earnings Call Summary
2026-08-07 04:19 · Yahoo
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
2026-05-26 16:33 · Yahoo
Ginkgo Bioworks Holdings Inc (DNA): What’s the Future of Autonomous Lab?
2026-05-22 12:36 · Yahoo
The Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Sales Forecasts
2026-05-13 11:41 · Yahoo
How The Ginkgo Bioworks (DNA) Story Is Shifting After The Biosecurity Divestiture And Target Cut
2026-05-11 19:13 · Yahoo
Ginkgo Bioworks Q1 Earnings Call Highlights
2026-05-10 03:05 · Yahoo
Ginkgo Bioworks Holdings, Inc. Q1 2026 Earnings Call Summary
2026-05-08 12:30 · Yahoo
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
2026-05-07 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.